Advertisement

Topics

Latest "Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children" News Stories

11:42 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children" found in our extensive news archives from over 250 global news sources.

More Information about Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children for you to read. Along with our medical data and news we also list Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Clinical Trials, which are updated daily. BioPortfolio also has a large database of Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Companies for you to search.

Showing "Study Anti reflux Medication Potential Treatment Glue Children" News Articles 1–25 of 45,000+

Tuesday 19th February 2019

Shield Therapeutics (STX) - Fortified for growth

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, out-licensing Feraccru to Norgine re-established an active salesforce in core EU5 territories and provided...


With new clinical trial results, Intercept Pharma will seek approval for first-ever treatment for NASH, a fatty liver condition. https://buff.ly/2Xcoed6 

With new clinical trial results, Intercept Pharma will seek approval for first-ever treatment for NASH, a fatty liver condition. https://buff.ly/2Xcoed6 

uLab Systems Partners with Drs. Tom Pitts & Duncan Brown to Bring Smile Arc to Aligners

uLab Systems, the creator of the cutting-edge aligner planning software, is happy to announce a partnership with Drs. Tom Pitts & Duncan Brown. Dr. Pitts and Dr. Brown are known for their revolutionary approach to orthodontic aesthetics. In fact, Dr. Pitts created the ‘Smile Treatment Design,’ an orthodontic protocol that focuses on smile arc, vertical ...


Akron Children’s Hospital Applies the Rothman Index to Real-Time Clinical Surveillance and Early Pediatric Sepsis Detection

Health system to test Rothman Index visual trend dashboards from PeraHealth to help reduce pediatric sepsis Akron Children’s Hospital is entering a partnership with PeraHealth to apply predictive analytics technology based on the Rothman Index. Recognized for leading the way to healthier futures for children through quality patient care, education, a...

Leading the way to self-care for acute pain

Pharmacists supporting patients to appropriately treat sudden, short bouts of pain through self-care will put patients at the centre of their treatment.

Fat Distribution Genetics Advanced through Targeting of Waist-to-Hip Ratio Genes

The identification of obesity-associated genes has been a growing area of research over the last two decades, altering our understanding of obesity. A new study broadens our understanding of genes’ role in obesity by targeting body-fat distribution. Specifically, the researchers present the first association of body-fat distribution, assessed by waist-to-hip ratio (WHR) adjusted for body ...

U.S. Cellular Announces The Future of Good 16 Under 16 Recipients

Wireless Carrier Awards $160,000 to Support 16 Youth Initiatives Impacting Communities Across the Country Through The Future of Good program, U.S. Cellular has selected 16 young humanitarians under 16 for the inspirational acts of good they do in their communities. Representing many types of service, these 16 youths were selected out of hundreds...

Local Physician Named President of the World’s Most Prestigious High-Risk Pregnancy Organization

Brian K. Iriye, MD, of the High Risk Pregnancy Center was named President of the Society of Maternal Fetal Medicine (SMFM) on Saturday, February 16, 2019. He was installed as the organization’s leader at the 39th annual meeting of the SMFM, which was held at Caesars Palace here in Las Vegas, NV. Established in 1977, the SMFM is the world’s premiere org...

Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*

Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carci...

Jobs versus Death Toll: Calculating Corporate Death Penalties

Is there a threshold an entire industry crosses when it does more harm than goo

Amgen Supports Science from Scientists’ Mission to Boost Interest in STEM Education

Boston non-profit and local STEMissaries company partner bring inspiring role models into elementary and middle school classrooms Science from Scientists (SfS), a non-profit dedicated to empowering youth to remain competitive in emerging STEM fields, has announced Amgen, one of the world’s leading

Climate change makes summer weather stormier yet more stagnant

Climate change is shifting the energy in th

Blood clot discovery could pave way for treatment of blood diseases

Led by the University of Exeter and funded by the British Heart Foundation, the team has developed a new technique that allows them to simultaneously measure blood clotting The post Blood clot discovery could pave way for treatment of blood diseases appeared first on Compelo Medical Devices.

LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression

Per its final decision, CMS has modified the NCD for VNS Therapy for TRD to include feedback received during the comment period in a manner that aligns the The post LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression appeared first on Compelo Medical Devices.

Special Learning Supports Ethics in the Field of (Applied) Behavior Analysis for the Global Autism Community

Why is Ethics an important topic for the field of behavior analysis? The most recently published (and widely adopted) 2018 Autism prevalence rate by the Centers for Disease (CDC) estimates that 1 in 59 children in the U.S. are affected by Autism Spectrum Disorder. It is generally accepted that Applied Behavior Analysis (ABA), an evidence-based behavioral intervention is considered the "gold s...

Ketamine Healing Clinic of Los Angeles Launches a Yearly Membership Program As Part of the Advanced Personalized Ketamine Protocol.

David Mahjoubi, MD of Ketamine Healing Clinic in Los Angeles offers Ketamine IV infusion therapy to effectively treat Depression, PTSD, and chronic pain. The clinic now offers a special yearly membership program to complement their Advanced Personalized Ketamine Protocol which helps patients reduce the cost of maintenance (“booster”) infusions. LOS ANGELES (PRWEB) February 19, 2019 The Ketami...

Crabapple Dental of Milton Now Offering Orthodontic Care

Dr. Sarah Roberts of Crabapple Dental at 12670 Crabapple Road in Milton, GA 30004 has expanded her menu of dental services to include a wide variety of orthodontic treatments. Along with general, restorative and cosmetic dentistry, the family-centered practice will now offer traditional braces, Invisalign and Six Month Smiles. MILTON, Ga. (PRWEB) February 19, 2019 Crabapple Dental is a full-servi...

New Ascom Myco™ 3 Smartphone Launched to Address Healthcare Efficiency and Collaboration Communication Challenges

Ascom, a global solutions provider focused on healthcare ICT and mobile workflows, announces the release of the Ascom Myco 3, its newest, innovative smart device purpose-built for healthcare, today at HIMSS19 where it is exhibiting and offering demos in booth #1533, February 11 - 15. Together, the Ascom Myco 3 and the Ascom Healthcare Platform bridge commu...

Head Position During Sleep Has Potential Implications for Neurodegenerative Disease

Could sleeping on your back increase your brain's risk of developing neurodegenerative disease? That possibility is revealed in a new study published in the Journal of Alzheimer's Disease. "We compared the in-home sleep patterns of patients with memory impairment resulting from neurodegenerative diseases to a large group of elderly wit...

Whole slide imaging equivalency and efficiency study: experience at a large academic center

FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection. 

In Midst Of Opioid Epidemic, States Look Toward Data Sharing, Medication-Assisted Treatment And More Solutions

States across the country have been beefing up their response to the opioid crisis by investing in treatment infrastructure, building databases, offering clean syringes and more. News on the crisis comes out of Maryland and Florida, as well.

Gr8 news for patients and @InterceptPharma! Also, as first positive P3 study in NASH, this will facilitate wave of new Rx! https://www.statnews.com/2019/02/19/with-nash-results-intercept-pharma-will-seek-approval-for-first-ever-treatment-for-fatty-liver-c

Gr8 news for patients and @InterceptPharma! Also, as first positive P3 study in NASH, this will facilitate wave of new Rx! https://www.statnews.com/2019/02/19/with-nash-results-intercept-pharma-will-seek-approval-for-first-ever-treatment-for-fatty-liver-condition/ …

$ABBV NDA Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis. Expects regulatory decision in Q3 2019 https://www.prnewswire.com/news-releases/abbvie-announces-new-drug-application-accepted-for-pri

$ABBV NDA Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis. Expects regulatory decision in Q3 2019 https://www.prnewswire.com/news-releases/abbvie-announces-new-drug-application-accepted-for-priority-review-by-us-fda-for-upadacitinib-for-treatment-of-moderate-to-severe-rheumatoid-arthritis-300797706.html …

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida Cell’s proprietary ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks